First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, announced yesterday that it has added Melvin P Weinstein, MD to its international clinical advisory board.
Dr Weinstein is the professor of Medicine and Pathology & Laboratory Medicine at Rutgers Robert Wood Johnson Medical School and is a fellow of the Infectious Disease Society of America, the American Academy of Microbiology and the American College of Physicians. He is presently the chair of the CLSI Subcommittee on Antimicrobial Susceptibility Testing.
David Macdonald, CEO of First Light Diagnostics, said, 'Dr Weinstein is a recognised expert in infectious disease and antimicrobial susceptibility testing (AST). We look forward to incorporating his valuable insights while implementing rapid phenotypic culture-free AST applications in the clinical laboratory, as an important member of our Clinical Advisory Board. Use of these applications will save lives, reduce healthcare cost and reduce the inappropriate use of antibiotics, which is driving the accelerating trend toward antimicrobial resistance.'
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer